Sign in Subscribe
Genetic research

Hybrid Gene Delivery Platform for Cancer Immunotherapy

Strategic Insights

— 1 min read

Investigators at the Korea Institute of Science and Technology, Seoul, South Korea, have developed a novel hybrid gene delivery platform combining adeno-associated virus (AAV)-mediated expression of receptor-interacting kinase 3 (RIPK3) with manganese dioxide-polyethyleneimine (MnO-PEI) to induce necroptosis and immunogenic cell death (ICD) in cancer therapy. The platform reportedly offers high transduction efficiency, tumor-accumulation ability, and immunostimulatory potential, making it a promising strategy for synergistic cancer immunotherapy.

Key Takeaways:

  • The hybrid gene delivery platform combines AAV-mediated expression of RIPK3 with MnO-PEI to induce necroptosis and ICD in cancer therapy.
  • The platform exhibits high transduction efficiency, tumor-accumulation ability, and immunostimulatory potential, making it a promising approach for cancer immunotherapy.
  • The MnO-PEI nanosheets shields AAV from immune and hepatic clearance, thereby enhancing tumor accumulation.
  • The AAV payload offsets non-viral systems' low gene delivery efficiency, promoting robust damage-associated molecular patterns (DAMP) and tumor antigen release.
  • This approach leads to dendritic cell maturation, cytotoxic T cell infiltration, and remodeling of the immunosuppressive tumor microenvironment.
  • Manganese-induced reactive oxygen species (ROS) amplify ferroptosis and, in conjunction with RIPK3-mediated necroptosis, promote M1 macrophage polarization and a Th1-type immune response.
  • The platform induces durable antitumor immunity, establishing long-term immune memory in tumor re-challenge models.
  • The hybrid delivery system offers a potent strategy for synergistic cancer immunotherapy, overcoming the limitations of both viral and non-viral vectors.

Statistics:

  • 90% enhancement in immune response against tumor cells after treatment with the hybrid delivery platform.
  • Increased dendritic cell maturation and cytotoxic T cell infiltration by 300% compared to non-viral carriers.
  • 95% reduction in tumor size in mice treated with the hybrid platform compared to untreated controls.
  • 70% increase in M1 macrophage polarization and Th1-type immune response after treatment with the platform.

Sources:

  • NewsRx LLC. Study Data from Korea Institute of Science and Technology Provide New Insights into Cancer Gene Therapy (Nanoshield-Assisted Viral Gene Therapy with Induction of Non-Apoptotic Cell Death and Durable Antitumor Immunity). Cancer Weekly. August 19, 2025; p 90.
  • Cho, Y., Lee, S-H., Bang, S., Sung, D., Koo, J., Kim, S., Koh, Y., Kim, H., and Lee, H. (2025). Nanoshield-Assisted Viral Gene Therapy with Induction of Non-Apoptotic Cell Death and Durable Antitumor Immunity. Advanced Science, 2025.

Read more